Realcan Pharmaceutical Group (002589.SZ) released its performance for the first three quarters, with a net profit of 19.22 million yuan, a decrease of 68.54%.
Connect global capital markets
Realcan Pharmaceutical Group (002589.SZ) released its third quarter report for 2023. The company's operating income for the first three quarters was 6.105 billion yuan, a decrease of 43.97% compared to the same period last year. The net profit attributable to the shareholders of the listed company was 19.22 million yuan, a decrease of 68.54% compared to the same period last year. The net loss attributable to the shareholders of the listed company, excluding non-recurring gains and losses, was 105 million yuan. The basic earnings per share were 0.0128 yuan.
Related Articles
Greenland HK (00337) contract sales in the first 4 months were about 880 million yuan, a year-on-year decrease of 69.3%.
ZENERGY(03677): The stable pricing period has ended, there will be no stable pricing actions and the oversubscription rights are void.
On May 8th, BEKE-W (02423) spent $3 million to repurchase 466,000 shares.
Greenland HK (00337) contract sales in the first 4 months were about 880 million yuan, a year-on-year decrease of 69.3%.
ZENERGY(03677): The stable pricing period has ended, there will be no stable pricing actions and the oversubscription rights are void.
On May 8th, BEKE-W (02423) spent $3 million to repurchase 466,000 shares.
RECOMMEND
General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025
Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025
Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025
